Available option
10mg
Lyophilised powder
- Strength
- 10mg
- Format
- Lyophilised powder
Bear Biotech catalogue
Semaglutide
Long-acting GLP-1 receptor agonist research material
- GLP-1 receptor signalling
- Incretin biology
- Metabolic research
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is Semaglutide?
Semaglutide is one of the most extensively characterised GLP-1 receptor agonists in modern metabolic research. Large controlled human programmes have examined glucose regulation, appetite-related physiology and metabolic outcomes using defined pharmaceutical formulations. Generic research material should not be presented as equivalent to those approved medicines.
Extensive human phase 3 evidence for defined pharmaceutical formulations; generic research material is not an approved medicine.
Research focus
Key research areas
Semaglutide research: long-acting GLP-1 receptor signalling
Semaglutide is a chemically modified GLP-1 analogue studied in defined pharmaceutical formulations. Those studies do not establish identity, purity, stability or equivalence of generic research material. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- GLP-1 receptor signalling
- Incretin biology
- Metabolic research
Representative primary research
Representative research
Research spans GLP-1 receptor signalling, pancreatic and glucose-regulatory physiology, appetite/energy-intake pathways, gastric physiology and metabolic disease endpoints.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗ Randomised phase 3 human trial; the defined study product does not establish catalogue material equivalence.
- Oral semaglutide 50 mg (OASIS 1) ↗ Randomised phase 3 human trial; the defined study product does not establish catalogue material equivalence.
- Phase 3 Trial of Semaglutide in MASH ↗ Randomised phase 3 human trial; the defined study product does not establish catalogue material equivalence.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- Semaglutide
- Research category
- Long-acting GLP-1 receptor agonist research material
- Evidence position
- Extensive human phase 3 evidence for defined pharmaceutical formulations; generic research material is not an approved medicine.
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
Which features of GLP-1-receptor signalling make Semaglutide scientifically distinctive?
Semaglutide is a long-acting GLP-1-receptor agonist studied through incretin signalling, glucose-regulatory physiology and appetite-related pathways. Its extensive literature concerns defined pharmaceutical formulations.
Why cannot evidence from approved Semaglutide formulations be assigned to generic research material?
Approved Semaglutide products have defined formulation, manufacturing and dosing characteristics. Generic research material is not equivalent merely because it carries the same compound name.
What does the extensive human evidence base for Semaglutide establish—and leave outside its scope?
Phase 3 and other human evidence establishes findings for specified approved formulations and protocols. It does not establish the identity, quality or clinical equivalence of a generic research vial.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.